<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797236</url>
  </required_header>
  <id_info>
    <org_study_id>2015-060</org_study_id>
    <nct_id>NCT02797236</nct_id>
  </id_info>
  <brief_title>SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of the SF2a-TT15 Conjugate Vaccine Against S. Flexneri 2a in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, single-center, single-blinded, observer-masked randomized, dose
      escalation (two doses), placebo-controlled study in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be assigned to one of two cohorts.

        1. Cohort 1 will receive the lower dose of 2 μg vaccine (with or without alum adjuvant) or
           matching placebo.

        2. Cohort 2 will receive the higher dose of 10 μg vaccine (with or without alum adjuvant)
           or matching placebo.

      Eligible subjects will be randomized to receive the 2 μg dose or 10 µg without or with alum
      or matching placebo, at a ratio of 3:1, as three single IM injections. There will be an
      interval of 28(±3) days) between each treatment.

      The study will be conducted in a stepwise approach in which a &quot;Pioneer&quot; Group of 2 subjects
      (one receiving the active vaccine and one receiving the matching placebo) will receive the
      first injection. These subjects will remain in-house for a 24-hours medical observation after
      the first injection (not required in the subsequent injections) Once it has been established
      that there are no safety concerns in the non-adjuvanted &quot;Pioneer&quot; Groups (and after no less
      than 48 hrs), the next &quot;Pioneer&quot; group (one subject receiving adjuvanted 2 μg vaccine and one
      receiving the matching alum placebo) will be injected.

      If no safety concerns are raised in this group also, after no less than 48 hrs, the rest of
      the subjects may receive the first injection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>12 months</time_frame>
    <description>Safety: Occurrence, frequency, severity, and duration of local and systemic adverse events (AEs) including clinically significant laboratory abnormalities, after administration of the SF2a-TT15 vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - humoral Immune response</measure>
    <time_frame>12 months</time_frame>
    <description>Serum antibody response (IgG IgM, IgA) to S. flexneri 2a LPS, following the administration of the various vaccine doses and antibody secreting cells to S. flexneri 2a LPS, following the administration of the various vaccine doses</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Shigellosis</condition>
  <condition>Bacillary Dysentery</condition>
  <arm_group>
    <arm_group_label>vaccine dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SF2a-TT15 vaccine, 2 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccine dose 1+ adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SF2a-TT15 vaccine, 2 μg + alum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccine dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SF2a-TT15 vaccine, 10 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaccine dose 2 + adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SF2a-TT15 vaccine, 10 μg + alum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tris buffer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + adjuvant</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tris buffer + Alum</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SF2a-TT15 vaccine</intervention_name>
    <arm_group_label>vaccine dose 1</arm_group_label>
    <arm_group_label>vaccine dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SF2a-TT15 vaccine + adjuvant</intervention_name>
    <arm_group_label>vaccine dose 1+ adjuvant</arm_group_label>
    <arm_group_label>vaccine dose 2 + adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo + adjuvant</intervention_name>
    <arm_group_label>Placebo + adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Subjects in general good health in the opinion of the investigator as determined by
             medical history, vital signs and a physical examination.

          -  Negative human leukocyte antigen (HLA) -B27 and no history of reactive arthritis

          -  Negative HIV, Hepatitis B and Hepatitis C serology tests.

          -  Blood levels of Shigella flexneri 2a LPS IgG antibodies ≤ percentile 80

          -  No known history of alcohol abuse

        Exclusion criteria

          -  Subjects with a history of clinically significant gastrointestinal disorders or with
             any history of frequent diarrhea, nausea or emesis, regardless of etiology.

          -  Individuals with immunosuppressive diseases or under immunosuppressive therapy

          -  History of culture-proven S. flexneri.

          -  Individuals who have household contact with/and /or intimate exposure to an individual
             with laboratory confirmed S. flexneri.

          -  Having travelled in countries/areas highly endemic for S. flexneri within 3 months
             prior to enrolment.

          -  Previous participation in any study in which a Shigella-vaccine candidate was
             administered.

          -  Known contraindication, hypersensitivity and/or allergy to the investigational product
             or its excipients.

          -  Known hypersensitivity and/or allergy to any drug or vaccine

          -  Women who are pregnant or are breast-feeding, or are of childbearing age who have not
             used or do not plan to use acceptable birth control measures, for the duration of the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tel Aviv Souraski Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2016</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>conjugate vaccine</keyword>
  <keyword>Shigella flexneri 2a</keyword>
  <keyword>safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Healthy adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysentery, Bacillary</mesh_term>
    <mesh_term>Dysentery</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

